Personnel Information

写真a

SATO Lubuna


Job title

Assistant Professor
To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2023.04
    -
    2024.09
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Infection Control and Prevention， Assistant Professor
  • 2024.10
    -
    2026.03
    Institute of Science Tokyo， -， Institute of Science Tokyo Hospital， Division of Infection Control and Prevention， Assistant Professor
  • 2026.04
    -
    Now
    Institute of Science Tokyo， -， Institute of Science Tokyo Hospital， Division of Integrated Facilities， Intensive Care Unit， Assistant Professor
To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Disseminated Mycobacterium abscessus Infection in a Three-Year-Old Girl With CHARGE Syndrome: A Case Report and Literature Review. 2025.07; 17 (7): e88327. ( PubMed, DOI )

  2. Factors associated with withholding of invasive mechanical ventilation in the early phase of the COVID-19 response and their ethical analyses. 2025.06; 5 (1): 30-36. ( PubMed, DOI )

  3. Urinary liver-type fatty acid-binding protein level as a prognostic indicator of acute kidney injury secondary to severe falciparum malaria. 2024.12; 13 (6): 522-527. ( PubMed, DOI )

  4. Unfractionated Heparin Safety in COVID-19: Incidence and Risks of Bleeding Complications in Japan. 2024.02; ( PubMed, DOI )

  5. Contact tracing in the hospital setting during the omicron wave of the coronavirus disease 2019 pandemic: persons and periods of concern for nosocomial infection prevention and control. 2024; 4 (1): e84. ( PubMed, DOI )

  6. Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved. 2023.10; 9 (10): e20568. ( PubMed, DOI )

  7. Treatment with tecovirimat of the first two cases of monkeypox in Japan. 2023.04; 29 (4): 418-421. ( PubMed, DOI )

  8. A case of prosthetic joint infection caused by Mycobacterium tuberculosis complicated secondary bacterial infection after knee joint replacement surgery. 2023.03; 29 (3): 367-370. ( PubMed, DOI )

  9. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial 2022.10; 10 (10): 985-996. ( DOI )

  10. A novel anticoagulation treatment protocol using unfractionated heparin for coronavirus disease 2019 patients in Japan, 2022. 2022.08; 4 (4): 233-236. ( PubMed, DOI )

  11. Case Report: Leptospirosis by Wild Rat Bite in Winter in Tokyo Metropolitan Area, Japan. 2022.05; 107 (1): 100-1. ( PubMed, DOI )

  12. Interferon lambda 3 in the early phase of coronavirus disease-19 can predict oxygen requirement. 2022.05; 52 (9): e13808. ( PubMed, DOI )

  13. Streptobacillus notomytis Bacteremia after Exposure to Rat Feces. 2022.04; 28 (4): 886-888. ( PubMed, DOI )

  14. Risk factors associated with asymptomatic hypoxemia among COVID-19 patients: a retrospective study using the nationwide Japanese registry, COVIREGI-JP. 2022.03; 15 (3): 312-314. ( PubMed, DOI )

  15. Fatty liver on computed tomography scan on admission is a risk factor for severe coronavirus disease. 2022.02; 28 (2): 217-223. ( PubMed, DOI )

  16. Clinical and radiological findings of silent hypoxia among COVID-19 patients. 2021.10; 27 (10): 1536-1538. ( PubMed, DOI )

  17. Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan. 2021.10; 28 (2): 206-210. ( PubMed, DOI )

  18. The influence of pre-admission antiplatelet and anticoagulation therapy on the illness severity in hospitalized patients with COVID-19 in Japan. 2021.10; 27 (10): 1498-1503. ( PubMed, DOI )

  19. Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan. 2021.09; 112 111-116. ( PubMed, DOI )

  20. External validation and update of prediction models for unfavorable outcomes in hospitalized patients with COVID-19 in Japan. 2021.07; 27 (7): 1043-1050. ( PubMed, DOI )

  21. Clinical course of alopecia after COVID-19. 2021.06; 107 255-256. ( PubMed, DOI )

  22. Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan. 2021.04; 27 (4): 1243-5. ( PubMed, DOI )

  23. Hemoptysis and a Newly Formed Lung Bulla in a Case of Convalescent COVID-19 Pneumonia. 2021.03; 60 (5): 803-805. ( PubMed, DOI )

  24. Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan 2021.03; 33 (4): 241-247. ( DOI )

  25. A new challenge of unfractionated heparin anticoagulation treatment for moderate to severe COVID-19 in Japan. 2020.06; 2 (3): 190-192. ( PubMed, DOI )

▼display all

To the head of this page.▲